Every 10-Q that CARDIFF LEXINGTN CORP (CDIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CDIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDIX filings page.
Cardiff Lexington Corporation filed its quarterly report for the period ended June 30, 2026. The company operates mainly through Nova Ortho and Spine, providing lien-based orthopedic healthcare services whose receivables are backed by attorney letters of protection.
Total assets were $30.7 million, up from $29.1 million at year-end, driven by higher accounts receivable of $23.7 million. Cash remained limited at $217,654. The capital structure is highly leveraged, with total liabilities of $27.1 million, including a healthcare receivables line of credit of $21.1 million, notes and related-party debt, and $1.09 million of derivative liabilities. Stockholders’ equity improved from a deficit of $(2.47) million to positive $1.76 million, primarily through equity issuances and reclassification of Series N preferred stock from mezzanine equity.
For the quarter, revenue was $2.16 million versus $2.79 million a year earlier; for six months, revenue was $4.38 million versus $5.70 million. The company reported a quarterly net loss of $2.48 million and a six‑month net loss of $5.57 million, compared with losses of $1.23 million and $1.68 million in the prior-year periods. Interest expense was substantial at $4.05 million for six months. Operating cash outflow improved to $(668,649) from $(1.89) million. Management disclosed an accumulated deficit of $85.6 million and stated that recurring losses and negative operating cash flows raise substantial doubt about the ability to continue as a going concern, and that continued operations depend on securing additional financing.
Cardiff Lexington Corporation reported a larger loss for the three months ended March 31, 2026 while relying heavily on debt financing. Revenue was $2,222,280, down from $2,915,567 a year earlier, reducing gross profit to $1,318,055. Operating results swung to a loss of $511,159, primarily due to $664,196 of share-based compensation and ongoing selling, general and administrative costs.
The bottom line was driven by $1,910,737 of interest expense and a $668,821 loss on derivative liabilities, producing a net loss of $3,092,074 and a basic and diluted loss per share of $0.23. Operating cash use was modest at $16,730, but the company raised $381,702 from financing, including $845,000 of new convertible notes.
At March 31, 2026, Cardiff held $683,507 in cash and $22,890,899 of accounts receivable tied to lien-based medical services, funded in part by an $18,922,173 line of credit under a $23,000,000 facility and $1,095,000 of convertible notes. Total liabilities were $24,630,858 against stockholders’ equity of $3,876,456 and an accumulated deficit of $82,855,513. Management disclosed substantial doubt about the company’s ability to continue as a going concern without additional capital.
Cardiff Lexington (CDIX) reported Q3 2025 results. Revenue rose to $3,058,740 from $1,355,641 a year ago, lifting gross profit to $1,909,579. Operating income reached $643,279, but higher interest expense of $1,765,528 drove a net loss of $1,144,299. For the nine months, revenue was $8,763,314 with a net loss of $2,821,471.
The balance sheet shows cash of $232,033, accounts receivable of $20,699,999, and line of credit borrowings of $14,727,190 as of September 30, 2025. The company continues to record healthcare receivables and revenue at a settlement realization rate of 42%. Accumulated deficit was $76,533,799 and management disclosed substantial doubt about continuing as a going concern absent additional capital.
The company restated 2024 cash flows to reclassify $1,953,667 of non‑cash interest to operating activities, with no change to total cash flows. Common shares outstanding were 19,904,708 as of September 30, 2025; 19,954,708 were outstanding as of November 10, 2025.